P. A. ROUTLEDGE; N. J. SCOLDING
To the editor: In their comparison of subcutaneous and continuous intravenous heparin in the treatment of acute deep venous thrombosis, Doyle and coworkers (1) show similar degrees of efficacy (in terms of prevention of pulmonary embolism) and incidence of adverse effects in the two treatment groups.
However, it is clear that the subcutaneous group achieved significantly better anticoagulation than the intravenous group (mean + SE activated partial thromboplastin times 59.8 ± 1.4 s and 53.4 ± 1.2 s respectively, P = 0.001) throughout the 7-day period of heparin treatment. The discrepancy was even greater in the first 3 days of
ROUTLEDGE PA, SCOLDING NJ. Heparin and Deep Venous Thrombosis. Ann Intern Med. ;108:488–489. doi: 10.7326/0003-4819-108-3-488_2
Download citation file:
Published: Ann Intern Med. 1988;108(3):488-489.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use